Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1
Global Diabetes Market Trends & Future Forecast Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1 report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: ( http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html )
Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence Region wise Diabetes Health Expenditure and Mortality Top 10 Countries Diabetes Population and Future Forecast Top 5 Countries Diabetes Drug Market and Future Forecast Top 7 Countries Insulin Market and Future Forecast Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market
Research Highlights
USA controls more than 50% of the total Diabetes Drug market share in 2009 Global Insulin Market is estimated to reach around US$ 17 Billion by 2013 China will have the second highest Insulin market share by 2012 replacing Germany DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015 GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015 Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015. Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030. Januvia is proving a blockbuster of DPP IV Inhibitors segment expected to be more than US$ 4 Billion by 2017 Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009 Japan Insulin market is expected to be more than US$ 1 Billion by 2010
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html
Related Reports
India Diabetes Care Devices Market Outlook to 2016 http://www.bharatbook.com/detail.asp?id=94991&rt=India-Diabetes-Care-Devices-Market-Outlook-to-2016.html
The Future of the Diabetes Care Devices Market to 2016 - The Key Demand Drivers Remain Intact http://www.bharatbook.com/detail.asp?id=130194&rt=The-Future-of-the-Diabetes-Care-Devices-Market-to-2016-The-Key-Demand-Drivers-Remain-Intact.html
Or
Contact us at
Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: info@bharatbook.com Website: www.bharatbook.com Follow us on twitter: http://twitter.com/3bbharatbook Please visit our blog at http://bharatbookseo.blogsome.com
Healthcare Medical Companies in India - New Delhi 17 January 2011 Akron Healthcare is engaged into Manufacturing, Distribution and Exports of Pharmaceutical Formulations and Medical Products. Akron Healthcare has modern facilities for large .. (55 Views)
